226 related articles for article (PubMed ID: 24191914)
21. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
Dechant KL; Goa KL
Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
[TBL] [Abstract][Full Text] [Related]
22. Rupatadine for the treatment of allergic rhinitis and urticaria.
Metz M; Maurer M
Expert Rev Clin Immunol; 2011 Jan; 7(1):15-20. PubMed ID: 21162645
[TBL] [Abstract][Full Text] [Related]
23. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
Janssens MM
Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life assessed by the effect of bepotastine besilate in patients with pruritus: importance of emotions score in atopic dermatitis.
Kawakami T; Kimura S; Haga T; Doi R; Kyoya M; Nakagawa K; Soma Y
J Dermatol; 2012 Jun; 39(6):527-30. PubMed ID: 22035542
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S; Sridhar S; Kumar K; Jayanthi CR; Gangasagara SB; Rathod BLS; Preethi B; Mittal P
Indian J Ophthalmol; 2021 Feb; 69(2):257-261. PubMed ID: 33463568
[TBL] [Abstract][Full Text] [Related]
26. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
[TBL] [Abstract][Full Text] [Related]
27. Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
González-Núñez V; Bachert C; Mullol J
Expert Opin Drug Saf; 2016 Oct; 15(10):1439-48. PubMed ID: 27500993
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
Carr WW; Nayak AS; Ratner PH; Gow JA; McNamara TR; Williams JI;
Allergy Asthma Proc; 2013; 34(3):247-54. PubMed ID: 23484763
[TBL] [Abstract][Full Text] [Related]
29. [Rhinoconjunctivitis. Highly selective therapy using topical H1-blockers].
HNO; 1996 Mar; 44(3 Suppl):1-4. PubMed ID: 9022382
[No Abstract] [Full Text] [Related]
30. Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.
Tanizaki H; Ikoma A; Fukuoka M; Miyachi Y; Kabashima K
Int Arch Allergy Immunol; 2012; 158(2):191-5. PubMed ID: 22286689
[TBL] [Abstract][Full Text] [Related]
31. Antihistamines in rhinoconjunctivitis.
Howarth P
Clin Allergy Immunol; 2002; 17():179-220. PubMed ID: 12113217
[TBL] [Abstract][Full Text] [Related]
32. [Second generation topical antihistaminics].
Pietrzkowicz M; Grzelewska-Rzymowska I
Pol Merkur Lekarski; 1999 May; 6(35):277-80. PubMed ID: 10437402
[TBL] [Abstract][Full Text] [Related]
33. Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin.
Tashiro M; Duan X; Kato M; Miyake M; Watanuki S; Ishikawa Y; Funaki Y; Iwata R; Itoh M; Yanai K
Br J Clin Pharmacol; 2008 Jun; 65(6):811-21. PubMed ID: 18410464
[TBL] [Abstract][Full Text] [Related]
34. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital.
Sruthi V; Reddy RN; Sowmini K; Grace NS
Indian J Pharmacol; 2020; 52(6):476-481. PubMed ID: 33666188
[TBL] [Abstract][Full Text] [Related]
35. Bilastine: a new H
Church MK; Labeaga L
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
[TBL] [Abstract][Full Text] [Related]
36. Rupatadine in allergic rhinitis and chronic urticaria.
Mullol J; Bousquet J; Bachert C; Canonica WG; Gimenez-Arnau A; Kowalski ML; Martí-Guadaño E; Maurer M; Picado C; Scadding G; Van Cauwenberge P
Allergy; 2008 Apr; 63 Suppl 87():5-28. PubMed ID: 18339040
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
Church MK
Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
[TBL] [Abstract][Full Text] [Related]
38. Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Izumi N; Mizuguchi H; Umehara H; Ogino S; Fukui H
Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):225-30. PubMed ID: 18597008
[TBL] [Abstract][Full Text] [Related]
39. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.
Tanizaki H; Kambe N; Nakamura Y; Tanaka A; Matsuda H; Miyachi Y
Int Arch Allergy Immunol; 2008; 145(4):277-82. PubMed ID: 18004068
[TBL] [Abstract][Full Text] [Related]
40. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L; Janakiraman A; Dudeja I; Sane K; Babu M
Indian J Ophthalmol; 2019 Sep; 67(9):1400-1404. PubMed ID: 31436181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
